Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hong-Hong Yan
Institutions:
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Southern Medical University
Observed institutions:
Sun Yat-sen University,
Guangdong General Hospital,
Guangdong Academy of Medical Sciences,
Sun Yat-sen University Cancer Center,
Guangdong Provincial People's Hospital,
State Key Laboratory of Oncology in South China,
Southern Medical University
show all 7
ORCID:
0000-0002-6228-2096
Observed ORCID:
0000-0002-6228-2096
OpenAlex ID:
A5110450305
Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
2012
·
She-Juan An
, Zhi-Hong Chen
, et al.
·
PLoS ONE
·
189
PDF
Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma
2016
·
Lie-Qiang Liao
, Hong-Hong Yan
, et al.
·
癌症:英文版
·
38
PDF
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
2025
·
Mei-Mei Zheng
, Qing Zhou
, et al.
·
Nature Medicine
·
37
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
2025
·
Yang-Si Li
, Qitao Yu
, et al.
·
Journal of Thoracic Oncology
·
24
PDF
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
2026
·
Anna Li
, Wei-Neng Feng
, et al.
·
Nature Communications
·
11
PDF
Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer
2025
·
Jia-Yi Deng
, Ming Gao
, et al.
·
Cancer Immunology Immunotherapy
·
4
PDF
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
2026
·
Chao Zhang
, Ben-Yuan Jiang
, et al.
·
EClinicalMedicine
·
2
Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification
2026
·
Lin-Xi Yin
, Zi-Jian Huang
, et al.
·
Lung Cancer
·
1
Pseudoprogression after neoadjuvant immunotherapy for resectable NSCLC: Incidence, PET/CT patterns, and differentiation.
2026
·
Li-Bo Berlin Tang
, Yi Pan
, et al.
·
Journal of Clinical Oncology
Implementing flexible and adapted follow-up strategies in a patient-centric, phase II trial of first-line lorlatinib for advanced ALK-positive non–small cell lung cancer (CTONG2203).
2026
·
Jia-Xin Lin
, Qing Zhou
, et al.
·
Journal of Clinical Oncology
PP01.42: Efficacy and Multi-omics Insights of Immune Checkpoint Inhibitors in NSCLC with Leptomeningeal Metastasis
2026
·
Li-Bo Tang
, Yang-Si Li
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
11
Citation count:
306
H-index:
5
I10-index:
5
Year
Topic
Type